its more aggressive use, discussed above, resurgence in the appreciation of mild TH and temperature regulation and its impact on acute brain injury emerged from the preclinical literature. The importance of "small differences" in temperature in impacting outcome in acute brain injury and the recognition that brain and core temperature were often somewhat different is often attributed to Busto et al (7) . In that study, a 2°C temperature difference during global ischemia-from 36°C to 34°C-markedly reduced neuronal death in rat brain, whereas increasing temperature to 39°C increased neuronal death. That article impacted the field of experimental brain injury (8) , and to this day, preclinical studies in experimental models of acute brain injury require temperature monitoring/control and often include brain temperature monitoring or surrogates such as temporalis muscle or tympanic membrane temperature. That report also challenged the notion that the benefits of TH were mediated solely by a reduction in energy demands below a critical threshold during ischemia-suggesting other undefined mechanisms. It was followed by studies in models of cardiac arrest (CA) in adult animals and of asphyxia in developing animals that set the stage for clinical trials showing benefit in both settings (9) (10) (11) (12) (13) (14) . The greatest efficacy of mild TH is seen in the treatment of birth asphyxia in term newborns with benefit versus standard of care on death, major disability, long-term outcome, and structural preservation on neuroimaging (15) . It is also ironic that the greatest benefit of TH in acute brain injury is seen in infants, given the longstanding concerns in neonatology about the highly deleterious consequences of cold stress (16) . Benefit of TH after asphyxia on mechanisms of special importance to the developing brain, such as apoptosis, has been suggested (17, 18) . Also, nonshivering thermogenesis is the primary mechanism of heat production in infants versus adults, which may necessitate a distinct series of developmentally regulated biochemical responses or gene-regulatory events induced by cold stress in newborn patients.
Contrasting the success seen with the use of mild TH in CA, despite early work showing the ability of TH to lower ICP, multicenter studies in TBI have failed to show benefit on long-term outcome. This included use in both adults and children in a variety of strategies (19) (20) (21) (22) (23) . Relatively unique complications associated with the use of TH in TBI have included concerns with hemodynamic instability during rewarming, which may be deleterious if ICP is elevated and concerns with the many drugs used to treat TBI and toxicities from them given the inhibition of cytochrome P-450-mediated drug metabolism by TH (24) (25) (26) . Some have suggested the need to use isolated brain cooling to achieve benefit without side effects in TBI (27) . Alternatively, the mechanisms underlying secondary injury in TBI may simply be less favorably influenced by TH than those in CA and counterbalanced by greater side effects.
TARGETED TEMPERATURE MANAGEMENT (TTM) IN NEUROCRITICAL CARE IN THE MODERN ERA
In panel discussions held by a committee charged to craft a consensus statement based on presentations made at the Society of Critical Care Medicine conference "Therapeutic HypothermiaTo Cool or Not To Cool?" in 2009, the editor of this journal, Dr. Buchman, suggested the term "TTM" to describe the scope and approach to the potential use of TH and temperature regulation across the field of critical care-and that term has been accepted. That result predicted some of the findings of clinical investigations that followed. In 2013, Nielsen et al (28) carried out an important study in more than 900 patients of the impact of 28 hours of mild TH (33°C) versus rigorously controlled "normothermia" (36°C) and reported an identical outcome in both groups, with ~50% of patients with severe disability, coma, or death. Interestingly, these outcomes mirrored those in the hypothermia groups in the successful CA trials reported a decade earlier, and although the generalizability of this study has been questioned due to the high percentage of cases with bystander cardiopulmonary resuscitation (73%), it suggested that rigorous fever control might underlie much of the benefit seen in the prior studies of TH after CA (HACA) in adults. Currently, both mild TH and TTM are used to treat adult CA victims (29) .
Recently, a landmark study (30) was published testing the effect of mild TH in 260 infants and children with out-ofhospital CA randomized to 33°C or 36.8°C for 48 hours-the THAPCA trial. Although the study failed to show benefit of TH on the primary outcome (survival with good neurobehavioral outcome at 12 mo), a trend with an 8% benefit on the primary outcome and an even stronger trend to reduced mortality was seen in the TH group. The study was powered to detect a 20% improvement-challenging for any therapy to achieve given the marked heterogeneity and severity of children with out-ofhospital CA (~50% had an underlying medical condition and only 40% had a witnessed arrest). It has been estimated that to detect a 10% benefit, more than 600 patients would need to be randomized to achieve 80% power. This important trial might be viewed as a window on future trial design for TH in pediatric CA, although some have suggested that given the lack of side effects observed, it actually supports use of TH in pediatric CA (31) .
A NEW CONCEPT, TTM VERSUS "ULTRA-MILD HYPOTHERMIA (UMH)"
These studies have raised many questions. Why has TH been so efficacious to treat birth asphyxia but less so after CA in children and adults? Is the efficacy of TTM the result of the prevention of fever? Does TTM at 36°C represent all that we can hope to achieve from "hypothermia"? A recent publication in Nature (32) introduced a novel concept for the possible benefits of deep TH that may shed some light on the entire field of TTM and TH. In that study, Prion-infected or or familial Alzheimer disease (XFAD) Alzheimer mice were briefly maintained in a hibernation-like state by rapid cooling over 1 hour to 16-18°C, kept at target temperature for 45 minutes, and given a 5-adenosine monophosphate (5-AMP) injection to further augment body heat reduction. Remarkably, this single brief intervention dramatically blunted the long-term consequences of these two neurodegenerative diseases including neuronal death, synaptic loss, and cognitive deficits assessed between 6 weeks and 3 months later. Importantly, the benefit was shown to be mediated to a large degree by the induction of the cold-shock protein RNA binding motif-3 (RBM3). It is unclear if 5-AMP (a vasodilator and hypothermia inducer) is an important component mediating RBM3 induction in this cooling protocol. However, RBM3 overexposure by lentivirus-mediated gene delivery produced a similar benefit in normothermic mice. Recently, work from our laboratory has suggested that TTM may be producing benefit beyond simply preventing fever. Jackson et al (33) reported that clamping isolated rat primary neurons (day in vitro [DIV]-6) in culture at 36°C for 24 or 48 hours markedly up-regulates RBM3 versus normothermia-although not quite to the level seen with exposure of these neurons to 33°C. DIV-6 neurons model many features of newborn neurons (34) . In contrast, DIV-26 neurons, modeling adult neurons exhibit a much more blunted up-regulation of RBM3 at 36°C or 33°C (33) . Given that a 1°C reduction in temperature is not believed to produce neuroprotection via mechanisms such as reducing energy demands, our findings suggest that TTM may exert benefit by mechanisms beyond simply preventing fever. TTM in its current form (controlling patients at 36°C) may represent a novel concept-namely "UMH." Equally exciting is the fact that we also discovered that two compounds, fibroblast growth factor-21 and melatonin (both of which are linked to endogenous control of temperature regulation in mammals), can substantially augment the up-regulation of RBM3 by exposure to 36°C in DIV-6 neurons (33) . This suggests that we may be able to pharmacologically augment novel benefits of extremely mild temperature reductions (1°C) with one or more drugs-attenuating long-term deleterious consequences of brain injury. Melatonin augmented neuroprotection by 33.5°C in a porcine model of perinatal asphyxia (34) . One could speculate that this approach could ultimately lead to a pharmacologic substitute for TH-since UMH regulates global gene transcription via RBM3. These are exciting new avenues for TH research applications for neurocritical care and beyond.
The concept that tiny shifts in temperature might impact CNS outcomes after injury, for better or worse, dates back to work in 1981, but was largely unnoticed. Berntman et al (35) showed that cooling adult rats to 36°C (vs 37°C) improved metabolic acidosis (blood pH and lactate) and increased adenosine triphosphate in the Levine model of hypoxic-ischemia. However, it is now better recognized that shifts in core temperature by only ± 1°C can engage a range of beneficial or deleterious biological, biochemical, and signaling responses, and our understandings of those nuanced effects on CNS recovery postinjury continue to evolve (Fig. 1) . Future studies using large-scale genomic, proteomic, and metabolic approaches are warranted, and should provide greater insight into how small differences in temperature can modulate brain injury.
Mounting evidence suggests that organisms are unexpectedly sensitive to tiny temperature shifts. Might we be overdue to reevaluate factors of temperature control in optimal preclinical study design as well? As discussed, Busto et al (7) changed table) . Selected studies supporting that 36°C activates neuroprotective pathways associated with targeted temperature management (TTM) or ultra-mild hypothermia (UMH) (28, 33, 35, (51) (52) (53) (right table) . Selected studies supporting that 38°C activates detrimental pathways associated with mild (subfebrile) hyperthermia. TTM/UMH holds promise as a potent and safe therapy to block detrimental pathways engaged on the right while simultaneously activating direct neuroprotective signaling pathways such as RNA binding motif-3 (RBM3) (50, 53-57). ATP = adenosine triphosphate, OOHCA = out-of-hospital cardiac arrest. preclinical practice by bringing awareness to the need for rigorously monitoring/controlling temperature in brain injury research. Controversial studies suggest that the environmental temperature needed to achieve thermoneutrality for a mouse (a temperature perceived as "comfortable") may be as high as ~30°C, whereas most animal housing facilities are kept at ambient temperatures 20-22°C (thermoneutral and comfortable for staff). This has led to the suggestion that animals used in research may be in a state of mild cold stress (36) (37) (38) (39) . TH has shown reproducible neuroprotection across brain injury models in rodents. It is possible that chronic exposure of rodents to perceived mild cold stress might precondition them to adopt an optimal TH response after injury and explain in part the failure in translation in some models to the clinical condition. What scenario best replicates the human condition?
Given that this review represents a discussion of novel approaches on the use of TH in neurocritical care and resuscitation, several others should be discussed (Fig. 2) . We mentioned that the failures of TH in randomized controlled trials studying TBI have greatly reduced enthusiasm for its use, despite the fact that it can reduce ICP (19) (20) (21) (22) (23) (24) (25) . However, the role of spreading depression in exacerbating secondary injury after TBI has emerged as a therapeutic target and few drugs block it (40, 41) . TH attenuates spreading depression, suggesting that isolated brain cooling in TBI or injury phenotype-targeted use of TH might be worthy of investigation. In the treatment of CA in adults and children, additional investigations are needed to define the optimal approach to temperature management including all facets of its use and potential adjuncts. Many important unanswered questions remain including the possibility of differential use based on arrest severity or phenotype (42) . In neonatology, where TH is standard of care for hypoxic ischemic encephalopathy (HIE) in term newborns, identifying therapeutic adjuncts to TH and determining whether it is efficacious in premature infants with HIE are being investigated (43) . TH in various applications is currently under investigation in spinal cord injury, stroke, and status epilepticus (44) (45) (46) . For example, in stroke, cooling might have potential via local delivery after clot retrieval to mitigate reperfusion injury (45) . Finally, use of an emergency deep hypothermic preservation to treat otherwise lethal exsanguination CA in victims of penetrating trauma-an approach pioneered by the late Dr. Peter Safar and known as emergency preservation and resuscitation-will soon be tested in a clinical trial by a team led by Dr. Samuel Tisherman, at Maryland Shock Trauma (47). We would be remiss to not indicate that controversy and unknowns even remain about preventing fever after acute brain injury-such as 1) the window of vulnerability of the injured brain to fever and 2) what is the optimal approach to fever in neurocritical care patients who are neither intubated nor sedated? Outside of preclinical (albeit compelling) studies (48) , clinically detrimental effects of fever after acute brain injury are only known in association studies (49, 50) .
CONCLUSIONS
We have come a long way in our understanding of the role of TH and TTM/UMH in neurocritical care. Recognition that in critical care, we need careful titration of all therapies, limiting side effects, and maximizing benefit is paramount to success. We also have learned that in neurocritical care, each disease (and patient) may exhibit a different response to temperature manipulation. We also recognize the importance of continual reexamination of interventions that have potent impact on patients, as our field evolves. The use of TH in neurocritical care exemplifies that "the good stuff keeps coming back" and merits ongoing reexamination as other aspects of care evolve. We believe that hypothermia is a complex therapy-"not a pill." And our understanding of how to optimize it is far from complete. Given the exciting new concepts that are emerging about the effects of TTM/UMH, we have come a long way from Aristotle's theory that the brain is merely a radiator to cool the heart!
